Vol. 51 Number 3 The Pharmacologist 2 0 0 9 Sep tember
Save the Date for: ASPET’s Annual Meeting at Experimental Biology April 24-28, 2010 Anaheim, CA
ASPET Program Information Inside!! Be sure to join us in sunny California!!
Important Dates:
September 1, 2009: Registration, Housing, Abstract Submissions open
November 4, 2009: Abstract Submission Deadline
February 24, 2010: Early Registration Deadline
March 19, 2010: Housing Reservation Deadline
April 24 - 28, 2010: Attend Experimental Biology 2010 in Anaheim!
Also Inside this Issue:
Message from President Cox EB Preliminary Program ASPET Membership Survey Results ASPET Committees P.B. Dews Award Lecture by Leonard Cook Division Executive Committees
A Publication of the American Society for 65 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics.
The EDITOR PHARMACOLOGIST Suzie Thompson
EDITORIAL ADVISORY BOARD Suzanne G. Laychock, PhD News John S. Lazo, PhD Richard R. Neubig, PhD
Message from the President ...... page 67 COUNCIL President EB 2010 Preliminary Program ...... page 69 Brian M. Cox, PhD President-Elect Membership Survey Results ...... page 77 James R. Halpert, PhD ASPET Committees ...... page 79 Past President Joe A. Beavo, PhD PB Dews Award Lecture ...... page 81 Secretary/Treasurer David R. Sibley, PhD Secretary/Treasurer-Elect Features Bryan F. Cox, PhD Past Secretary/Treasurer Susan G. Amara, PhD Journals ...... page 84 Councilors Suzanne G. Laychock, PhD Public Affairs & Government Relations ...... page 85 John S. Lazo, PhD Division News: Executive Committees ...... page 87 Richard R. Neubig, PhD Chair, Board of Publications Trustees Chapter News James E. Barrett, PhD Mid-Atlantic Chapter Meeting ...... page 89 Chair, Program Committee Jack Bergman, PhD Members in the News ...... page 90 Chair, Long Range Planning Committee Staff News ...... page 90 Joe A. Beavo, PhD Executive Officer New ASPET Members ...... page 91 Christine K. Carrico, PhD In Sympathy ...... page 94 The Pharmacologist (ISSN 0031-7004) Obituary is published quarterly in March, June, Robert F. Furchgott ...... page 95 September, and December by the American Society for Pharmacology and Sachindra N. Pradhan ...... page 96 Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814- 3995. Annual subscription rates: $20.00 for ASPET Members; $45.00 for Announcements U.S. nonmembers and institutions; $70.00 for nonmembers and institutions outside the U.S. Single copy: $20.00. Membership Information ...... page 99 Copyright © 2009 by the American Membership Application ...... page 100 Society for Pharmacology and Experimental Therapeutics, Inc. All rights reserved. Periodicals postage paid at Bethesda, MD. GST number for Canadian subscribers: BN:13489 2330 RT. 2010 Dues Notices will be ASPET assumes no responsibility for the statements and opinions advanced mailed out shortly. Please by contributors to The Pharmacologist.
Deadlines for submission of material for check your mailboxes and publication: Issue 1, March 1; Issue 2, June 1; Issue 3, September 1; and Issue 4, December 1. send in payment by Postmaster: Send address changes to: The Pharmacologist, ASPET, 9650 January 1, 2010. Rockville Pike, Bethesda, MD 20814- 3995.
A Publication of the American Society for 66 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
MESSAGE FROM THE PRESIDENT
Dear ASPET Members,
I am honored to serve as President of ASPET, and thank the members for electing me. I look forward to working with Council and members of the society to advance the interests of members and of pharmacologists in general. Our efforts will be more effective the greater the participation of members in the activities of the society; please get involved! I hope to hear from many of you on issues of concern and I welcome your suggestions for enhancing the support the society offers to professional pharmacologists.
The recession has not left the Society entirely unscathed. Our reserves have been reduced, but careful management has limited the decline relative to that seen by some other professional societies. Nevertheless, we are projecting a significant budget deficit for the current year. The good news is that most of our sources of revenue and most of our necessary expenditures are holding steady. We are carefully monitoring all sources of revenue and expenditure to limit operational losses and are taking steps to ensure that our reserves begin to recover. You can be assured that the society will continue to support its outstanding publications, and will continue our efforts to make our annual meetings an exciting opportunity for pharmacologists to get together to advance the discipline. Despite the financial concerns, the Society has committed significant funding over the past year to the improvement of our web site. Our previous web site design has served us well for almost a decade, but constraints implicit in the original design limited our options for expanded functionality and it was beginning to appear outdated. Under the leadership of Christie Carrico and Past-President Joe Beavo, the website has been re-designed and a Web Editor, Jonathan Maybaum, a professor at the University of Michigan, has been appointed after a national search. The Web Editor’s role is to oversee utilization of the re-designed site to improve our communications with members. We would also like to make the website a recognized resource for reliable information on drugs and their actions for the general public. We encourage you to visit the new web site where, hopefully, you will find material of interest to you. Your comments are welcomed, and we hope you will offer your own thoughts on any issue of concern. We are now evaluating how to best serve the needs of ASPET’s divisions through the web site. Additionally, we hope to attract the interests of professional pharmacologists who are not currently members through the presentation of current information of importance to all pharmacologists. As ASPET moves into its second century, the society will need to play an increasing role in keeping pharmacologists informed on issues in the public affairs arena that could significantly impact the future careers and research opportunities available to pharmacologists. We anticipate that members and the society will need to be more vigilant in following developments affecting pharmacologic research, and more active in representing our views on the difficult choices that will have to be made as limited critical resources are allocated (or not allocated) for biomedical research. Additionally, major changes are taking place in both graduate and medical education. The society and its members need to be aware of these changes, and to present a coherent voice explaining the important role of pharmacologists in the training of informed and effective health care professionals. We can expect the Public Affairs Committee and the Public Affairs Office under Jim Bernstein to play an increasingly important role in the society in coming years, and I encourage your enthusiastic involvement in their activities. Enhanced communication through the web will be very important for the society in all these areas as we move forward. Finally, I need to extend my thanks to society members who serve on Council or on ASPET’s standing committees and to the outstanding people in the ASPET Office who manage the increasingly complex affairs of the society on a day-to-day basis. Without the active participation of many of our members and the excellent service provided by the office staff, the society would not be able to serve the profession effectively. I offer my personal thanks to all for making my task easier, and encourage everyone to become even more involved in supporting ASPET so that we, in turn, can support the discipline. I look forward to hearing from you!
Sincerely,
A Publication of the American Society for 67 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
EB 2010 PRELIMINARY PROGRAM 2010 ASPET Annual Meeting at EB 2010 April 24-28, 2010 Anaheim, California
ASPET Preliminary Program
Friday & Saturday, April 23-24
The Behavioral Pharmacology Society Meeting
Saturday, April 24 Afternoon Sessions
2010 Teaching Institute: Simulation in Pharmacology Education: Going Beyond Mannequins Chair: L.M. Crespo, University of Central Florida
Diversity Committee Workshop: Traditional and Alternative Career Paths in Rough Economic Times Chairs: M. Davila-Garcia, Howard University and Marcus Delatte, FDA
Speakers: K.A. Albert, Louisiana State University P.A. Ardayfio, Eli Lilly & Co. L. Stewart, Caterpillar, Inc
Graduate Student/Postdoc Colloquium: Leadership
ASPET Business Meeting & Opening Reception
Sunday, April 25 Morning Sessions
WIP Into Shape Networking Walk
Diversity Mentoring Breakfast
Regenerative Pharmacology and Stem Cell Research for Tissue and Organ Repair: State-of-the-Art Sponsored by the Divisions for Integrative Systems, Translational & Clinical Pharmacology; Cardiovascular Pharmacology; Drug Discovery, Drug Development & Regulatory Affairs; and Neuropharmacology Chairs: D.C. Marshall, Ferring Pharmaceuticals, Inc. and G.J. Christ, Wake Forest Institute for Regenerative Medicine
Stem and Progenitor Cells for Vascular and Muscle Tissue Engineering: Regenerative Pharmacology and Enabling Technologies Required for Clinical Translation G.J. Christ, Wake Forest Institute for Regenerative Medicine
Orphan Cytochrome P450 and Other Drug Metabolizing Enzymes Sponsored by the Divisions for Drug Metabolism; Integrative Systems, Translational & Clinical Pharmacology; and Toxicology Chair: F.P. Guengerich, Vanderbilt University School of Medicine
Overview: The General Problem of Characterizing Proteins of Unknown F.P. Guengerich, Vanderbilt University School of Medicine FunctionTransgenic Mouse Approaches to P450 Function F. J. Gonzalez, NIH, National Cancer Institute Use of Humanized Mice in the Study of the Function of Human UGT Enzymes J.C. Stevens, Pfizer, Inc.
A Publication of the American Society for 69 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
EB 2010 PRELIMINARY PROGRAM
In Vitro LC-MS Approaches to Deorphanization of Cytochrome P450 Enzymes Z. Tang, Vanderbilt University School of Medicine
When the Smoke Clears, There's More to Neuronal Nicotinic Acetylcoline Receptors Sponsored by the Divisions for Behavioral Pharmacology; Drug Discovery, Development & Regulatory Affairs; Molecular Pharmacology; and Neuropharmacology Chairs: M. Picciotto, Yale University School of Medicine and L. McMahon, University of Texas Health Science Center at San Antonio
Nicotinic Chemistry and Drug Discovery H. Rollema, Pfizer, Inc. Electrophysiological Studies of Novel, Low Efficacy Agonists of nAChRs R. Papke, University of Florida In Vivo Pharmacological Evidence for Low Efficacy Agonist Actions of nAChR Ligands I: Drug Discrimination, Seizure Threshold, and Cardiovascular Effects in Rodents E. Jutkiewicz, University of Michigan In Vivo Pharmacological Evidence for Low Efficacy Agonist Actions of nAChR Ligands II. Drug Discrimination and Schedule-Controlled Behavior in Monkeys and Mice L. McMahon, University of Texas Health Science Center at San Antonio Nicotine Addiction and Depression: Human Studies T. George, University of Toronto Nicotine Addiction and Depression: Rodent Studies M. Picciotto, Yale University School of Medicine
Spatial and Temporal Organization of Cell Signaling Sponsored by the Division for Molecular Pharmacology and the American Society for Biochemistry & Molecular Biology Chair: J.D. Scott, University of Washington School of Medicine Howard Hughes Medical Institute
Synaptic Organization of Neuronal Signaling M. Dell'Acqua, University of Colorado Denver School of Medicine Anchored PKA and Immune Function K. Taske'n, University of Oslo AKAPs and Adenylyl Cyclases C.W. Dessauer, University of Texas Medical School Cell Signaling in Space and Time J.D. Scott, University of Washington School of Medicine Howard Hughes Medical Institute
New Therapeutic Approaches to Combat Arterial Thrombosis Sponsored by the Divisions for Cardiovascular Pharmacology; Drug Discovery, Development & Regulatory Affairs; and Integrative Systems, Translational & Clinical Pharmacology Chairs: J. Kermode, University of Mississippi Medical Center and Z.M. Ruggeri, The Scripps Research Institute
How Differences in Metabolic Activation of Prasugrel and Clopidogrel Contribute to Differences in Efficacy for Blockade of the Platelet P2Y12 Receptor J.A. Jakubowski, Eli Lilly & Company Arterial Thrombosis: How it Occurs and How to Combat It Z.M. Ruggeri, The Scripps Research Institute Upcoming and Future Targets on the Platelet for Antithrombotic Drugs J. Kermode, University of Mississippi Medical Center Protease-Activated Receptor-1 (PAR-1) on the Platelet as a Novel Target for Antithrombotic Drugs L.K. Jennings, University of Tennessee Health Science Center
Applying Web 2.0 Technologies in Teaching Pharmacology: Developing the Tool Box Sponsored by the Divisions for Pharmacology Education and Integrative Systems, Translational & Clinical Pharmacology Chairs: W.B. Jeffries, University of Vermont College of Medicine and J.L. Szarek, The Commonwealth Medical College
A Publication of the American Society for 70 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
EB 2010 PRELIMINARY PROGRAM
Creative Use of Web 2.0 Technologies for Medical Education: Specific Examples W.B Jeffries, University of Vermont College of Medicine Rethinking Education for the Net-Geners J.L. Szarek, The Commonwealth Medical College
Sunday, April 25 Afternoon Sessions
Applications of Stem Cell Therapies in Clinical Development and Regenerative Pharmacology in Organ Repair Sponsored by the Divisions for Integrative Systems, Translational & Clinical Pharmacology; Cardiovascular Pharmacology; Drug Discovery, Development & Regulatory Affairs; and Neuropharmacology Chairs: C. Felder, Eli Lilly & Co. and A. Chen, University of Pittsburgh School of Medicine
Vascular/Endothelial Progenitor Cells: Applied Pharmacology with Clinical Outcomes A. Chen, University of Pittsburgh School of Medicine
Industrial Academic Partnerships: A New Era (Workshop) Sponsored by the Divisions for Drug Metabolism; Behavioral Pharmacology; Drug Discovery, Development & Regulatory Affairs; Pharmacology Education; and Integrative Systems, Translational & Clinical Pharmacology Chair: L. Wienkers, Amgen, Inc.
Insights on Joint Academic-Industrial Research Collaborations K. Seibert, Pfizer Global Research and Development The Consortium Model for Strengthening Industrial/Academic Relations T.A. Baillie, University of Washington The Academic Sabbatical in the Pharmaceutical Industry: Opportunity to Enhance Both Missions T. Tracy, University of Minnesota College of Pharmacy
Stimulus-Bias in an Allosteric World: Relevance to CNS Drug Target Validation Sponsored by the Divisions for Neuropharmacology and Drug Discovery, Development & Regulatory Affairs Chairs: A. Christopoulos, Monash University and C. Felder, Eli Lilly & Company
Importance of Stimulus Bias in Discovery and Utility of Allosteric Modulators of GPCR's as Therapeutic Agents P.J. Conn, Vanderbilt University Medical Center Quantifying Functional Bias at 7TM Receptors T. Kenakin, GlaxoSmithKine Allosteric Modulator-Engendered Stimulus Trafficking: Implications for Drug Discovery A. Christopoulos, Monash University Deciphering the Complexity of Allosteric Modulation from In Vitro Pharmacology through In Vivo Behavioral Assessment C. Felder, Eli Lilly & Company
Receptor-Independent Activators of G-Protein Signaling in the Nervous System Sponsored by the Divisions for Drug Discovery, Development & Regulatory Affairs and Molecular Pharmacology Chair: S.M. Lanier, Medical University of South Carolina
Regulation of GPCR Functions by Non-G-Protein Partners Q. Wang, University of Alabama, Birmingham AGS3 and AGS4 in G-Protein Signaling J. B. Blumer, Medical University of South Carolina GIV/Girdin, a Non-Receptor GEF for Gαi, is Required for Cell Migration M.G. Farquhar, University of California, San Diego The Role of AGS3 in Craving, Alcoholism and Addiction I. Diamond, University of California, San Francisco Tctex1 (AGS2) and Neural Stem Cell Maintenance D. Kaplan, University of Toronto Regulation of G-Protein Signaling and Expression by the Non-Receptor GEFs Ric-8A and Ric-8B G. Tall, University of Rochester
A Publication of the American Society for 71 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
EB 2010 PRELIMINARY PROGRAM
P. B. Dews Lecture in Behavioral Pharmacology
In Vivo Animal Modeling in Drug Discovery and Development: Multiple Approaches to Predict Clinical Efficacy in CNS Disorders Sponsored by the Divisions for Behavioral Pharmacology; Integrative Systems, Translational & Clinical Pharmacology; and Neuropharmacology Chair: S. Rosenzweig-Lipson, Wyeth Research
Use of Transgenic Animal Models in the Discovery of Drugs for Neurological Disorders R. Paylor, Baylor Medical College Cognition in NHP's: Utility of Translation into the Clinic D.M. Hutcheson, Maccine Pte, Ltd. Behavior-Driven Approach to Drug Discovery P. McGonagall, PsychoGenics, Inc. Animal Models in Psychiatry, Tried and True vs. Disease-Based, What's the Advantage? K.L. Marquis, Wyeth Research
Monday, April 26 Morning Sessions
Julius Axelrod Lecture Speaker: Palmer Taylor, University of California, San Diego
Julius Axelrod Symposium Chair: Palmer Taylor, University of California, San Diego
Extracellular Matrix Proteins of the CCN Family as Therapeutic Targets Sponsored by the Divisions for Drug Discovery, Development & Regulatory Affairs and Molecular Pharmacology Chairs: J. Heller Brown, University of California, San Diego and L.J. Lau, University of Illinois at Chicago
Introduction to the Biology and GPCR Regulation of CCN Proteins J. Heller-Brown, University of California, San Diego CCN Proteins and Inflammation L.F. Lau, University of Illinois at Chicago CCN1/CYR61 in Breast Cancer R. Lupu, Mayo Clinic CCN Proteins and Inflammation D. Brigstock, The Research Institute at Nationwide Children's Hospital
Introduction of Drug Safety (Pharmacovigilance) Into Curricula Sponsored by the Divisions for Pharmacology Education; Behavioral Pharmacology; Cardiovascular Pharmacology; Drug Discovery, Development & Regulatory Affairs; Drug Metabolism; Integrative Systems, Translational & Clinical Pharmacology; Molecular Pharmacology; Neuropharmacology; and Toxicology Chairs: G. Dunaway, Southern Illinois University and J. Strandhoy, Wake Forest University
Recent Advances in the Neuropharmacology of Anxiety: Implications for Novel Therapeutics Sponsored by the Divisions for Integrative Systems, Translational & Clinical Pharmacology and Neuropharmacology Chair: B. Greenwood-Van Meerveld, University of Oklahoma Center for Neuroscience
Overview of Anxiety: Current and Future Treatment Approaches B. Greenwood-Van Meerveld, University of Oklahoma Center for Neuroscience GABA-A Receptors and Therapeutics: Beyond Benzodiazepines L. Gerak, University of Texas Health Science Center Visceral Pain Related Anxiety: Role of Glucocorticoids B. Meyers, University of Oklahoma Health Sciences Center Pathophysiology of Panic Disorder: Neuroimaging Studies of Monoaminergic Neurotransmitter Systems
A Publication of the American Society for 72 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
EB 2010 PRELIMINARY PROGRAM
W. Drevets, NIH, National Institute of Mental Health Molecular Pharmacology of Anxiety: Role of Orphan FX/Nociceptin Kelly Standifer, University of Oklahoma Health Sciences Center
Wnt Signaling and Development: Conventional and Unconventional GPCR's Mechanisms Sponsored by the Divisions for Molecular Pharmacology and Neuropharmacology Chair: C.C. Malbon, State University of New York at Stony Brook
Wnt-Frizzled Signaling: The Non-G-Protein-Coupled Mechanisms R. Van Amerongen, Stanford University Wnt-Frizzled Signaling: The G-Protein-Coupled Mechanisms and Targets L. Katanaev, University of Konstanz Wnt-Frizzled Signaling and the Function of ß-Arrestins G. Schulte, Karolinska Institute Wnt-Frizzled Signaling and LRP5/6 X. He, Children's Hospital and Harvard Medical School Wnt-Grizzled Signaling and Protein Domains H. Wang, State University of New York at Stony Brook
Monday April 26th Afternoon Sessions
Division for Neuropharmacology Post Doctoral Award Finalists
B.B Brodie Lecture in Drug Metabolism
Division for Drug Metabolism and James Gillette Best Paper Award Platform Session Chairs: S. Leeder, Children’s Mercy Hospital and Clinics and J.C. Stevens, Pfizer, Inc
Division for Behavioral Pharmacology Symposium: Stress, Cognitive Function, and Monoaminergic Mechanisms in Psychiatric Disorders Chairs: D. Morilak, University of Texas Health Science Center at San Antonio and A. Frazer, University of Texas Health Science Center at San Antonio
Catecholaminergic Regulation of Impulse Control J. D. Jentsch, University of California, Los Angeles Role of the Medial Prefrontal Cortex in Stress Resilience and Vulnerability S. Maier, University of Colorado Molecular Mechanisms Underlying Stress-induced Prefrontal Cortical Dysfunction: Relevance to Mental Illness A. Arnsten, Yale University School of Medicine Monoaminergic Mechanisms Linking Stress, Cognitive Dysfunction and its Treatment in Depression and Anxiety Disorders D. Morilak, University of Texas Health Science Center
Division for Cardiovascular Pharmacology Junior Scientists' Competition
Paul Vanhoutte Lecture in Cardiovascular Pharmacology
Division for Pharmacology Education Session
Tuesday, April 27 Morning Sessions
Ray Fuller Lecture in the Neurosciences: Transcriptional and Epigenetic Mechanisms of Drug Addiction Speaker: E.J. Nestler, Mt. Sinai School of Medicine
Ray Fuller Symposium: Epigenetic Mechanisms of Learning and Memory Chair: E. J. Nestler, Mt. Sinai School of Medicine
A Publication of the American Society for 73 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
EB 2010 PRELIMINARY PROGRAM
DNA and Histone Methylation in Learning and Memory D. Sweatt, University of Alabama, Birmingham Role of CBP in Long-Term Memory T. Abel, University of Pennsylvania Histone Acetylation in Hippocampus in Long-Term Memory Storage in Health and Disease L-H. Tsai, MIT Role of Histone Deacetylases in Memory Formation and Retrieval M. Wood, University of California, Irvine
Regulating the Regulators: Redox Regulation, Stress Response Proteins and Apoptosis Sponsored by the Divisions for Toxicology and Drug Metabolism Chair: D. St. Clair, University of Kentucky
Introduction to the Connections Between Cellular Redox Status and Transcription Response D. St. Clair, University of Kentucky ROS and p53 Modulators in Cancer Specific Apoptosis S. Lee, Harvard Medical School p53 Regulates Mitochondrial Function P.M. Hwang, NIH, National Heart, Lung, and Blood Institute SIRT3 is a Mitochondrial Tumor Suppressor Gene Required for Maintenance of Mitochondrial Integrity and Oxidative Metabolism During Stress D. Gius, NIH, National Cancer Institute Mitochondria: Novel Regulators of the Keap1/Nrf-2 Antioxidant Pathway A. Landar, University of Alabama, Birmingham The Bi-directional Role of p53 on MnSOD Expression S. Dhar, University of Kentucky
New Insights About an "Old" Second Messenger, cAMP: Implications for Cardiovascular Pharmacology Sponsored by the Divisions for Cardiovascular Pharmacology and Molecular Pharmacology Chair: P.A. Insel, University of California, San Diego
Cyclic AMP: New Discoveries, Insights, and Therapeutic Opportunities P.A. Insel, University of California, San Diego Plasma Membrane Efflux: An Unappreciated Determinant of cAMP Signaling in Vascular Cells J. Hulot, Inserm U621 Adenylyl Cyclases: Unappreciated Regulators, Genetic Variants and Potential for Novel Therapeutics R. Feldman, Robarts Research Institute Epacs: cAMP Effectors that Link to Low Molecular Weight G-Proteins M. Schmidt, University of Groningen
High-Resolution Structural Approaches to Understanding GPCR Activation Sponsored by the Division for Molecular Pharmacology and the American Society for Biochemistry & Molecular Biology Chair: B. Kobilka, Stanford University
Long Time-Scale Molecular Dynamics Simulations of G-Protein Coupled Receptors R. Dror, D.E. Shaw Research The Structure of a Constitutively Active Mutant of Rhodopsin: Implications for the Activation of GPCRs G. Schertler, MRC Centre Laboratory of Molecular Biology Allersteric Regulation on Ligand Binding by G-Proteins R. Sunahara, University of Michigan Medical School Mechanism of Receptor G-Protein Interaction H. Hamm, Vanderbilt University
A Publication of the American Society for 74 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
EB 2010 PRELIMINARY PROGRAM
Integrating Genetics, Genomics and Pharmacology: How the Pharmacogenomics Knowledge Base Catalyzes Pharmacogenomic Research and Translational Medicine Sponsored by the Divisions for Integrative Systems, Translational & Clinical Pharmacology; Behavioral Pharmacology; Cardiovascular Pharmacology; Drug Discovery, Development & Regulatory Affairs; Drug Metabolism; Pharmacology Education; Molecular Pharmacology; Neuropharmacology; and Toxicology Chair: A. Shuldiner, University of Maryland School of Medicine
Genome-Wide Association Studies in Pharmacogenomics E. Dolan, University of Chicago Pharmacogenomics and Membrane Transporters: A Critical Component of Pharmacokinetics D. Kroetz, University of California, San Francisco The PharmGKB database and the Pharmacogenetics Research Network: What it Can Do for Your Research R. Altman, Stanford University Knowledge Base Catalyzed Pharmacogenomic Research and Translational Medicine Curation Process at Pharm GKB L. Gong, Stanford University
Tues April 27th Afternoon Sessions
Epigenetic Regulation: Concepts and Applications in Psychiatric, Neurological and Substance Abuse Disorders Sponsored by the Divisions for Behavioral Pharmacology; Drug Discovery, Development & Regulatory Affairs; Integrative Systems, Translational & Clinical Pharmacology; and Neuropharmacology Chairs: J.E. Barrett, Drexel University College of Medicine and M.A. Nader, Wake Forest University School of Medicine
Epigenetic Principles and Mechanisms Underlying Nervous System Function in Health and Disease M.F. Mehler, Albert Einstein College of Medicine Therapeutic Application of Histone Deacetylase Inhibitors for CNS Disorders A.G. Kazantsev, Harvard Medical School Studies of Schizophrenia Through the Prism of Epigenetics S. Akbarian, University of Massachusetts Medical Center Epigenetic Alterations of miRNA in Neuropathic Pain Reveal Novel Regulatory Mechanisms S. Ajit, Wyeth Research Epigenetic Mechanisms in Drug Addiction S.J. Russo, Mount Sinai School of Medicine
Division for Drug Discovery, Development & Regulatory Affairs Symposium: Protease-Activated Receptors: New Roles and Regulatory Mechanisms Chair: J. Trejo, University of California, San Diego
Dysregulation of Protease-Activated Receptor Signaling in Cancer J. Trejo, University of California, San Diego The Role of PAR1 in Neuronal Function and CNS Disease S. F. Traynelis, Emory University ß-arrestins as Mediators of PAR-2 Induced Inflammation K. DeFea, University of California, Riverside Proteinase-Mediated Signaling and Inflammation: Tissue Kallikreins (KLKs) and More M. D. Hollenberg, University of Calgary
Division for Integrative Systems, Translational & Clinical Pharmacology Session Chair: A. Geadigk, Children's Mercy Hospital & Clinics
Division for Toxicology Symposium: ABC Transporters, Their Role in Physiology, Toxicology and Cancer Chair: J. Schuetz, St. Jude's Children's Research
A Publication of the American Society for 75 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
EB 2010 PRELIMINARY PROGRAM
Regulation of ABC Transporters at the Blood-Brain Barrier: New Targets for CNS Therapy B. Bauer, University of Minnesota College of Pharmacy Applying Principles Derived from Laboratory Studies to Multidrug Resistance in Human Cancers M.M. Gottesman, NIH, National Cancer Institute The Contribution of ABC Transporters to Drug Resistance in a Realistic Mouse Mammory Tumor Model P. Borst, University of Amsterdam Transcriptional Regulation of Hepatobiliary Transporters C.D. Klaassen, University of Kansas Medical Center
Division for Molecular Pharmacology Postdoctoral Award Finalists
Wednesday, April 28 Morning Sessions Only
Protein-Protein Interactions and Modulation of Drug Metabolism Sponsored by the Divisions for Drug Metabolism; Integrative Systems, Translational & Clinical Pharmacology; and Toxicology Chair: T. Tracy, University of Minnesota College of Pharmacy
Microsomal Monooxygenase as a Multienzyme System: Exploring Protein-Protein Interactions of Cytrochromes P450 D. Davydov, University of California, San Diego UGT-CYP Protein Interactions: Role of Conjugating Enzymes in Modulating Oxidative Enzyme Activity Y. Ishii, Kyushu University Effect of P450-P450 Complex Formation on Monooxygenase Function W. L. Backes, Louisiana State University School of Medicine
Role of Mitochondria in Drug Hepatotoxicity: A Tale of Stress Sponsored by the Divisions for Toxicology; Drug Metabolism; and Integrative Systems, Translational & Clinical Pharmacology Chair: N. Kaplowitz, University of Southern California
Mitochondrial Permability Transition - Target and Executioner in DILI J. Le Masters, Medical University of South Carolina Compartmentation of Oxidative Stress Defense in Mitochondria: Implications of Drug Toxicity D. Jones, Emory University School of Medicine Threshold for Mitochondrial Participation in Idiosyncratic DILI U. Boelsterli, University of Connecticut Interplay of Signal Transduction and Mitochondria in the Acetaminophen Model D. Han, University of Southern California
Sphingosine 1-Phosphate Signaling as a Therapeutic Target Sponsored by the Divisions for Molecular Pharmacology, Drug Discovery, Development & Regulatory Affairs; Integrative Systems, Translational & Clinical Pharmacology; and Neuropharmacology Chair: K.R. Lynch, University of Virginia
Shingomab in Oncology and Macular Degeneration R.A. Sabbadini, Lpath Therapeutics, Inc Fingolimod: Experience with Autoimmune Disease V. Brinkmann, Novartis Pharma AG Sphingosine 1-Phosphate Drug Discovery K.R. Lynch, University of Virginia S1P and Pain S.P. Welch, Virginia Commonwealth University
A Publication of the American Society for 76 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
ASPET MEMBERSHIP SURVEY RESULTS
Thank you to all ASPET members who participated in the 2009 ASPET Membership Survey. Your input is very important to us and we appreciate all opinions, criticisms and suggestions offered. The survey was designed to give each of our members a voice in the Society, and by getting your input, we hope to continue to strive to improve our benefits and develop new programs to fit your needs. While we are not able to implement every suggestion, we do take every comment seriously and we are happy to share the results of the survey with you.
General Membership:
We are happy to report that 78.4% of survey respondents feel that ASPET is meeting their professional needs. Only 3.1% reported that ASPET was not meeting their professional needs, and 18.5% were unsure. Of the respondents who indicted no or unsure, most of them were very new to ASPET membership (just joined less than a year ago) or they were retired members. Through our journals, the annual meeting, public affairs updates, and our divisions, we hope to provide you with many resources to help you progress professionally. If there are things you feel we need to improve, please feel free to contact us at [email protected].
88.3% of survey respondents indicated that ASPET communicates with its membership adequately. We are happy that a majority of respondents felt satisfied with our level of communication, however we are always striving to improve our communication. We recently re-vamped the ASPET website, making it more user friendly and easier to navigate. We also added several features such as our President’s Blog, discussion groups, RSS feeds about public affairs news, etc. We also created an ASPET Facebook page and Twitter account to communicate with members using these new media. We continue to use email as our primary means of communication – any important announcements, deadlines, and news always go out through email, so be sure to keep your eye out for email communications from us. If you have recently changed email addresses, be sure to let us know so that we can keep our communication with you up-to-date. You can make contact information changes online at the ASPET website at www.aspet.org or you can email us at [email protected].
In asking about the level of participation in ASPET by our members, we found the majority of respondents do participate in Society activities on some level. We are pleased to see this high level of participation because without your input in surveys, your sponsorship of other members, your volunteerism on committees, and attendance at our annual meeting, our Society could not exist. We also asked if you felt that ASPET gives you adequate opportunities to participate in Society affairs, and again a strong majority said yes. When asked if members wanted to be more involved in ASPET, 66% said they do not. We hope that you will always take advantage of any opportunities that interest you; however, your level of participation is completely up to you. If you want to get more involved, you are always welcome to contact us. But if you want to enjoy the benefits of membership without taking too much of your time from other areas of your professional life, we are pleased to provide that for you as well.
ASPET Annual Meeting
As most members know, ASPET meets on an annual basis with Experimental Biology. As we strive to improve attendance at our annual meeting and provide interesting programming, we asked a series of questions related to the meeting. It is unfortunate that only 34% of respondents were able to attend EB this year. However, of those that did attend, 94% found our annual meeting to be successful and informative, and 92% found the program sessions to be compelling and interesting. We were also encouraged to see that 36% of members indicated they were already planning to attend EB in 2010, and 37% were still deciding.
Our next annual meeting will be held April 24-28, 2010 in sunny California. We hope that you will make plans to attend as we have a very exciting program lined up, and we expect it to be a great meeting. By meeting with EB, we provide our members with not only our own programming directly related to pharmacology, but also five other related societies’ programming with just one low registration fee. There are more than 50 concurrent scientific sessions open to all attendees spanning the scientific disciplines of each of the sponsoring societies of EB, over 400 exhibit booths representing nearly 300 companies, and 4 days of poster sessions with over 5,000 poster displays and author presentations, not to mention the awards and travel grants we provide. It’s a great meeting to be a part of, and we hope that you will make the next one! For more information about our meeting visit www.aspet.org or www.experimentalbiology.org.
A Publication of the American Society for 77 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
ASPET MEMBERSHIP SURVEY RESULTS
Small Meetings/Colloquia (Separate from the Annual Meeting)
We also asked a series of questions regarding your interest in attending smaller meetings/colloquia held separately from EB. In the recent past, smaller meetings/colloquia have had low attendance and participation, so we wanted to see if there was still interest in these types of meetings. 68% of respondents indicated some interest in smaller meetings, but most indicated that the topic would have to be relevant to their area of work or study. More people were interested in scientific programming over professional development programming, but 34% indicated that having both types of programming at a small meeting would be beneficial. 82% of respondents agreed that they would be interested in seeing the work of young scientists, post-docs and students at a smaller meeting.
When asked which month would be the best month to hold a smaller meeting, there was no strong majority for any month. However, 32% indicated September as a good month to attend a small meeting held by ASPET. Most respondents indicated that they would be willing to pay $75 - $125 for a small meeting registration. 49% of respondents indicated that they could spend a few hours a month to help organize programming for a small meeting, while 29% said they would not be able to help organize at all.
Any suggestions and ideas for smaller meetings or the large annual meeting are always welcome. Please direct them to the Meetings Manager at [email protected].
Molecular Interventions
A print copy of Molecular Interventions is mailed to all ASPET members as a member benefit. Members also have access to the online version of the journal. MI operates at an annual loss of approximately $400,000. It will require additional support from members to continue publication. We asked members specifically what is the maximum you are willing to pay in addition to your current membership dues to continue to receive Molecular Interventions. 52% of members were not willing to pay any more in membership dues to help sustain Molecular Interventions. 35% were willing to pay $25, 11% were willing to pay $50 and 2% were willing to pay more. Many members indicated that they would be willing to drop their print copy of Molecular Interventions if they could have online access. While the future of this journal is not yet clear, we thank you for your honest evaluation of the monetary value of the journal.
New Technologies
We have had very mixed reviews about the new technologies that are cropping up all around us including Facebook and Twitter. While some members have indicated that these new media are a waste of time, others have encouraged us to participate. From a professional Society standpoint, most societies are jumping on the Facebook and Twitter bandwagon and feel that is important to get involved, even if it turns out to be a fad later on. ASPET views Facebook and Twitter as additional mechanisms of promoting our Society and communicating with members and those interested in pharmacology. While it is certainly not the main way we communicate with members, it is now one of the ways we stay in touch with the community that is on Facebook and Twitter. If you haven’t already, come check us out! http://bit.ly/3zSe86 and www.twitter.com/aspet
A strong majority of our members indicated that they still want to receive their breaking public affairs news through email notification and the website over Facebook and Twitter. We are pleased to let you know that we still provide this service and have improved our website to help facilitate this.
We also asked members if they used a PDA, iPhone or Kindle. These are all very new technologies that are quickly becoming popular, and especially our journals department is interested in possibly exploring these technologies for your journal access. The majority of respondents do not own these devices and do not plan to purchase them in the near future. For those that do own them, 21% indicated they would use their devices to browse ASPET journals.
A Final Note
Once again, we want to thank you for your valuable input. As expected, there was a mixed bag of comments and suggestions and each one has been read and evaluated. They will be made available to the ASPET Council this fall. Please feel free to contact us with any further comments to [email protected]. We hope to continue to serve you in all your membership needs.
A Publication of the American Society for 78 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
ASPET COMMITTEES 2009-2010
Committees Established by Bylaw: Dennis C. Marshall, Member (2010) Kim A. Neve, Member (2010) Jeffrey C. Stevens, Member (2011) COUNCIL Mary E. Vore, Member (2010) Brian M. Cox, President (2010) Scott A. Waldman, Member (2011) James R. Halpert, President-Elect (2010) Jordan E. Warnick, Member (2010) Joe A. Beavo, Past-President (2010) Christine K. Carrico, Ex Officio David R. Sibley, Secretary/Treasurer (2010) Bryan F. Cox, Secretary/Treasurer-Elect (2010) Committees Established by Resolution: Susan G. Amara, Past-Secretary/Treasurer (2010) Suzanne G. Laychock, Councilor (2011) John S. Lazo, Councilor (2010) COMMITTEE ON COMMITTEES Richard R. Neubig, Councilor (2012) James R. Halpert, Chair (2012) James E. Barrett, Ex Officio (2011) Joe A. Beavo, Member (2010) Jack Bergman, Ex Officio (2011) Brian M. Cox, Member (2011) Christine K. Carrico, Ex Officio Christine K. Carrico, Member
NOMINATING COMMITTEE COMMITTEE ON GRADUATE RECRUITMENT AND Joe A. Beavo, Chair (2010) EDUCATION Michael H. Court, Member (2010) Joey V. Barnett, Chair (2010) John R. Hepler, Member (2010) Suzanne B. Bausch, Member (2010) Emily M. Jutkiewicz, Member (2010) Lynn M. Crespo, Member (2010) John C. Kermode, Member (2010) Alejandro M. Mayer, Member (2012) Richard B. Kim, Member (2010) Thomas F. Murray, Member (2011) Jack Bergman, Ex Officio (2011) Lisa M Schrott, Member (2012) Christine K. Carrico, Staff Liaison Sarah H. Lindsey, Student/Fellow (2010) E. Aaron Runkle, Student/Fellow (2011) FINANCE COMMITTEE Meera Sridharan, Student/Fellow (2010) David R. Sibley, Chair (2010) Brian M. Cox, Council Liaison (2011) Susan G. Amara, Member (2010) Christine K. Carrico, Staff Liaison James E. Barrett, Member (2010) Brian F. Cox, Member (2010) LONG RANGE PLANNING COMMITTEE Haian Fu, Member (2010) Joe A. Beavo, Chair (2010) Benjamin R. Yerxa, Member (2010) James E. Barrett, Member (2011) Charles O. Rutledge, Member (2010) Brian M. Cox, Member (2011) Christine K. Carrico, Ex Officio Martha I. Davila-Garcia, Member (2011) James R. Halpert, Member (2012) Investment Sub-Committee Suzanne G. Laychock, Member (2011) Charles O. Rutledge, Chair (2010) John S. Lazo, Member (2010) Susan G. Amara, Member (2010) Richard R. Neubig, Member (2012) Bryan F. Cox, Member (2012) Christine K. Carrico, Ex Officio David R. Sibley, Member (2011) James W. Gibb, Member (2011) COMMITTEE ON DIVERSITY Brian M. Cox, Ex Officio (2010) Martha I. Davila-Garcia, Chair (2011) James R. Halpert, Ex Officio (2011) Eric L. Barker, Member (2011) Christine K. Carrico, Ex Officio Marcus Delatte, Member (2011) Sakina E. Eltom, Member (2012) PROGRAM COMMITTEE Gilandra K. Russell, Student/Fellow (2010) Jack Bergman, Chair (2011) Joey V. Barnett, Committee Liaison (2010) Ralph J. Bernacki, Member (2012) Carol A. Paronis, Committee Liaison (2011) Anindya Bhattacharya, Member (2011) Bryan F. Cox, Council Liaison (2012) Christian C. Felder, Member (2010) Christine K. Carrico, Staff Liaison Charles P. France, Member (2010) Bruce A. Freeman, Member (2011) COMMITTEE ON PUBLIC AFFAIRS John R. Glowa, Member (2012) Ronald N. Hines, Chair (2010) John C. Kermode, Member (2010) Namandje N. Bumpus, Member (2011)
A Publication of the American Society for 79 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
ASPET COMMITTEES 2009-2010
Steven I. Dworkin, Member (2010) ASPET Awards Committees: Edward D. French, Member (2010) Gerald J. Schaefer, Member (2010) James E. Barrett, Council Liaison (2011) ASPET AWARDS COMMITTEE James S. Bernstein, Staff Liaison John S. Lazo, Chair (2010) Jerry J. Buccafusco, Member (2013) COMMITTEE ON WOMEN IN PHARMACOLOGY Melanie H. Cobb, Member (2012) Carol A. Paronis, Chair (2011) Joann L. Data, Member (2011) Lori A. Birder, Member (2011) Randy A. Hall, Member (2012) Andria L. Del Tredici, Member (2010) Jeffry L. Vaught, Member (2010) Theresa M. Flitz, Member (2012) Stephen M. Lanier, Member (2010) Ann T. Hanna-Mitchell, Member (2011) Jelveh Lameh, Member (2012) ASTELLAS AWARDS COMMITTEE Susan F. Steinberg, Member (2010) Susan G. Amara, Chair (2010) Remy L. Brim, Student Representative (2011) Bryan F. Cox, Member (2012) Kristy L. Houck, Student Representative (2010) Suzanne G. Laychock, Member (2011) Margarita L. Dubocovich, Advisory (2010) John S. Lazo, Member, Member (2010) Alice M. Young, Advisory (2012) Richard R. Neubig, Member (2012) Suzanne B. Bausch, Committee Liaison (2010) David R. Sibley, Member (2011) Susan G. Amara, Committee Liaison (2010) Martha I. Davila-Garcia, Ex Officio (2011) B.B. BRODIE AWARD IN DRUG METABOLISM Christine K. Carrico, Staff Liaison COMMITTEE Eric F. Johnson, Chair (2013) COUNCIL OF DIVISION CHAIRS Maria A. Correia, Member (2010) Joe A. Beavo, Chair (2010) Frederick P. Guengerich, Member (2013) Debra Diz, Member (2011) John Y. Kao, Member (2010) George A. Dunaway, Member (2011) Curtis D. Klaassen, Member (2013) Margaret E. Gnegy, Member (2011) Michael F. Jarvis, Member (2011) JULIUS AXELROD AWARD COMMITTEE Thomas A. Kocarek, Member (2010) David R. Sibley, Chair (2012) Qiang Ma, Member (2011) Randy D. Blakely, Member (2012) Dennis C. Marshall, Member (2010) Lee Eiden, Member (2012) Michael A. Nader, Member (2010) Edward T. Morgan, Member (2010) Kim A. Neve, Member (2011) Kim A. Neve, Member (2011) Jack Bergman, Ex Officio (2011) Patricia K. Sonsalla, Member (2010) Dona L. Wong, Member (2011) WEB ADVISORY COMMITTEE Brian M. Cox, Chair (2010) P.B. DEWS AWARD COMMITTEE Jonathan Maybaum, Editor (2012) Nancy A. Ator, Chair (2013) Bradley T. Andresen, Member (2012) Robert L. Balster, Member (2012) Joey V. Barnett, Member (2012) Jonathan L. Katz, Member (2013) Michael F. Jarvis, Member (2011) Roger D. Spealman, Member (2010) John S. Lazo, Member (2011) Jeffrey M. Witkin, Member (2013) Carol A. Paronis, Member (2012) Alice M. Young, Member (2013) Dianne M. Perez, Member (2012) Jeffrey C. Stevens, Member (2012) James S. Bernstein, Member James E. Barrett, Ex Officio (2010) David R. Sibley, Ex Officio (2010) George A. Dunaway, Ex Officio (2010) Christine K. Carrico, Ex Officio Suzie M. Thompson, Ex Officio
A Publication of the American Society for 80 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
P. B. DEWS AWARD LECTURE
Lecture given at Experimental Biology 2006 by the P. B. Dews Lifetime Achievement Award Recipient:
Reflections of an Industrial Scientist on a Lifetime in Behavioral Pharmacology
Leonard Cook
More than seventy years ago, my receiving an award such as this from this society would have been inconceivable. As a matter of fact, even being invited to become a member of ASPET would have been a bit of “compromise” for the society. I was a scientist working in the pharmaceutical industry. Scientists working in industry at that time were not always considered entirely “legitimate scientists,” or as much devoted to good quality or objective research as their academic colleagues. Clearly the research efforts of scientists working in the pharmaceutical industry over the past half century have changed that perception.
I received my Ph.D. in pharmacology at Yale Medical School in 1951. The Department of Pharmacology, chaired by Professor William Salter, was a very unusual department, as the training program was specifically oriented to fill the substantial need for pharmacologists in the rapidly growing pharmaceutical industry after the Second World War. The department focused on the strategy and specific laboratory techniques for drug discovery and evaluation, and delivered “hands on” training.
After I defended my thesis research, I received several job offers. Four of them were from pharmaceutical companies (including Abbott, Merck, Smith Kline and French, and Carters), and two were from medical schools. One of those was from the Department of Pharmacology at Harvard Medical School. (I would have been Peter Dews’ colleague.) After much deliberation, I decided to accept the offer from Smith Kline and French in Philadelphia. In my innocent enthusiasm, I showed the offer letter to my mentor who clearly did not share the department chairman’s philosophy of training for the needs of industry. His response was traumatizing. “If I thought that you were going to be a prostitute, and enter the pharmaceutical industry, I would never have accepted you as my student!” It took years for him to forgive me for this sinful decision.
After all my years in the pharmaceutical industry, I have never regretted my decision. The opportunities provided in industry to further my scientific career were unique. In the 1950s and 1960s at Smith, Kline and French, there was wide latitude in the research areas from which I was allowed to select. The choice was essentially my own, and I received strong support. In the early 1950s, I developed a “Drug Potentiation” program on the basis of a chance discovery, which yielded SKF 525A, a compound which enhanced the pharmacological effects of a wide variety of drugs. SKF 525A allowed me to collaborate in a joint research program with Bernard Brodie and Julie Axelrod at NIH, helped to open up an entirely new area of drug metabolism, and provided a major stimulus to my early career and reputation.
In addition, the research on SKF 525A led me to test a compound called Largatil from Rhone Poulenc, a French drug company. Largatil had been offered previously to several American companies as an antihistaminic. It also was reported to have “drug potentiation” properties, and on this basis I requested a few grams for a comparison with SKF 525A. I found that, in addition to enhancing effects of other sedatives, Largatil had an unusual sedative effect on the animals. The animals appeared indifferent to environmental stimuli and uniquely placid. With support from management, I pursued the behavioral effects of Largatil, and in the process over the next several years developed one of the first and largest behavioral pharmacology laboratories in the world.
Largatil was, of course, chlorpromazine (and eventually was called “Thorazine”). Its useful clinical effects were subsequently identified by two French psychiatrists, Pierre Delay and Jean Deniker, and to say it revolutionized psychiatry may be an understatement. In addition to its efficacy in schizophrenia, its “drug potentiation” properties and its “hypothermic” effects were found useful in cardiac surgery by Henri Laborit. My expanded research program was pivotal in describing the constellation of pharmacological and psychopharmacological properties of chlorpromazine. As a result, I continued to receive support from management to follow my instincts in expanding laboratory efforts in behavioral pharmacology. I hired (unheard of until then) experimental psychologists to help me develop behavioral tests in animals to explore psychopharmacological effects. I oriented these young behavioral scientists, including Roger Kelleher, Charles Catania, Bob Schuster, Arnold Davidson, William Holz, and others like electrophysiologist Keith Killam, towards pharmacology. Our laboratory became internationally known, and our publications became an important part of the foundation of literature in behavioral pharmacology. Importantly, the extensive work we carried out examining the effects
A Publication of the American Society for 81 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
P. B. DEWS AWARD LECTURE of various pharmacological agents on a variety of behaviors in animals clearly showed that behavior was a reliable subject for pharmacological studies and led to the acceptance of behavioral pharmacology as a legitimate discipline.
During that time behavioral research in several other laboratories was developed to a very sophisticated level. In particular, the techniques developed and the analyses utilized by B. F. Skinner and his students using schedules of reinforcement were especially useful in identifying subtle and characteristic properties of psychopharmacological agents. The drugs were evaluated in detail, which yielded a more nuanced and informative description that went far beyond previous gross characterizations such as “stimulant” or “sedative.” The behavioral procedures clearly separated and classified antipsychotics and antianxiety/hypnotic compounds more clearly than ever before. Also established in the late 1950's and 1960's were methods for evaluating “cognitive enhancing” agents for the field of “performance enhancement.”
The value of “whole animal” behavioral research was further supported after we published a paper demonstrating the strong correlation of the effects of a number of drugs in inhibiting the conditioned avoidance response in rats, with their clinical potencies for producing anti-psychotic effects (see Table 1). No other laboratory technique in pharmacology demonstrated such predictability, which firmly established the value of the behavioral research. As a result, the company had no hesitancy to rely primarily on behavioral pharmacology data for selecting which new agents should go into the long and expensive process of drug development.
As history shows, the introduction of chlorpromazine into the expanding market of mental disease therapy led to competition. Miltown and the benzodiazepines appeared initially as possible competitors of chlorpromazine, before their own more appropriate place as anti-anxiety agents was established. As in the case of antipsychotic drugs, behavioral techniques again showed their capacity to very specifically identify compounds useful for certain clinical syndromes. Conflict, or punished, behavior, very specifically identifies compounds effective in treating clinical anxiety. Anxiolytics specifically reverse the suppression of behavior by punishment. The potencies of compounds in producing anti- punishment effects in animals is highly correlated with their antianxiety clinical potencies (Table 2). Again, as was shown in the activity of antipsychotics, animal behavioral techniques are highly valuable in predicting and evaluating anxiolytics.
In recent years, I have seen a substantial decline in the use of many previously established valuable behavioral techniques for the evaluation of drugs. I currently see sophisticated molecular biology results being used to correlate with the most unsophisticated behavioral measures, such as the use of simple locomotor activity. It is unfortunate for biological science to see this retreat from the use of sophisticated behavioral techniques and analyses to what can only be described as non-specific or relatively crude behavioral measures. I would urge (even implore) the rediscovery and redevelopment of the valuable animal behavioral techniques and analyses used in the past for correlation with today’s advances in molecular biology. Several years ago, Louis Lasagna, one of our great clinical psychopharmacologists, remarked that those that used highly specialized cutting-edge biological techniques and tried to relate their findings to psychiatric problems using rudimentary and unsophisticated behavioral approaches were the “idiot savants” of biomedical research.
Nonetheless, when I look over the approximately 60 years of development of behavioral pharmacology and its important contributions to the overall field of pharmacology, I believe it is a “far cry” from my experience in my journal club at Yale in 1948. At that time, during my first week as a graduate student, I chose to report on a paper from a psychology journal describing drug effects on certain psychological tasks. I was sternly told by the professor, “Cook, we don’t deal here with spooky pharmacology!” A remark like that is less likely today due to the advances made with unique psychopharmacological agents studied with sophisticated behavioral techniques and analyses.
I had the privilege to work in the dawning age of modern psychopharmacology. Working with chlorpromazine in the 1950s enabled me to see a fascinating transition of how physicians viewed mental disease. I heard opinions from well established psychiatrists, physicians, psychologists, and others who viewed the etiology of mental disease in different ways, including character flaws, poor upbringing, socially toxic early experiences, and bizarre infections. I vividly recall visiting prominent psychiatrists in the 1950s to discuss the pharmacology of chlorpromazine, hoping they would try it with some of their patients. More than one would incredulously ask, “Do you expect a drug to erase or modify the impact of early motherhood experiences?” Amazingly, one of the greatest barriers to the early testing of chlorpromazine in psychiatric disease and its eventual establishment as a legitimate therapy in schizophrenia was the general resistance and reluctance within the medical profession and the dominance of psychotherapy at that time. On the other hand, after speaking with Paul Hock in 1954 about my preclinical data he became interested in clinical studies with chlorpromazine.
A Publication of the American Society for 82 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
P. B. DEWS AWARD LECTURE
His high standing and clinical experience influenced others in the medical profession. It took the imagination and courage of people like Paul Hock, Hans Lehman, and others to initially try chlorpromazine in the clinic.
The times and opportunities were fortunate for me. I do not feel that I experienced any significant barriers or limitations on my career because I was an “industrial” scientist. I became a member of ASPET in 1956. I was elected President of the American College of Neuropsychopharmacology (ACNP) in 1982 and was the first industrial scientist to be an officer in that distinguished society. I was a charter fellow, and a member of the International College of Psychopharmacology (CINP). In 2006, I was honored when the CINP presented to me their “Pioneer Award” in the field of psychopharmacology, recognizing the impact of my early research. It has been an exciting career, enhanced by warm friendships with colleagues from industry, government, and academia, and from all over the world. I still enjoy these warm relationships and friendships. I am deeply grateful that this organization, ASPET, which accepted me as a member over 50 years ago and which several years previous to that had reluctance to do so for industrial scientists, has recognized me with this “Lifetime Achievement” award for my research in industry. When I reflect back to the parting words of my mentor at Yale and the “risk” I took by deciding to enter the pharmaceutical industry for my career, I know that I made the right choice.
TABLE 1: Comparison of pre-clinical potency determined by conditioned avoidance response (CAR) in rates with clinical potency
Rat Conditioned Clinical Avoidance ED 50 Preclinical Dose for Severe Mental & Clinical Rank Compound Value Rank Order Emotional Disorders Order (mg/kg of base, p.o.) (mg/day, oral)
Trifluoperazine 0.9 1 3-30 1
Perphenazine 1.1 2 8-40 2
Thiopropazate 1.5 3 15-30 3
Triflupromazine 4.0 4 100-300 5
Prochlorperazine 4.2 5 50-150 4
Chlorpromazine 9.9 6 200-600 6
Promazine 20.3 7 400-1000 7
Modified from Cook, L. and Kelleher, R. T. Drug effects on the behavior of animals. Annals of the New York Academy of Sciences, 1962, 96, 315-335.
TABLE 2. Comparison of clinical potency with rat test results
Effects on Punished Responding in Clinical Antianxiety Effects Rats Compound Minimally Average Daily Preclinical Rank Clinical Rank Effective Dose Dose Order Order (mg/kg, p.o.) (mg, oral) Diazepam 0.63 1 20 1 Chlordiazepoxide 2.2 3 40 2 Oxazepam 1.25 2 49 3 Phenobarbital 4.5 4 115 4 Amobarbital 5.0 5 175 5 Meprobamate 62.5 6 1410 6
Modified from Cook, L. and Davidson, A. B. Effects of behaviorally active drugs in a conflict-punishment procedure in rats. In S. Garattini, E. Mussini, and L. O. Randall (eds.) The Benzodiazepines, Raven Press, New York, 1973, pp. 327-345.
A Publication of the American Society for 83 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
Journals
Next JPET Editor Selected
Following an extensive search that began last spring, the Board of Publications Trustees Executive Committee has selected Dr. Michael F. Jarvis to succeed Dr. Rick Schnellmann as the next editor of the Journal of Pharmacology and Experimental Therapeutics. Dr. Jarvis will fully assume the editorship on January 1, 2010, but is likely to start handling manuscripts in December as part of the editorial transition.
Dr. Schnellman’s second three-year term as JPET editor will conclude at the end of 2009. Editors of all ASPET journals may serve for no more than six years. The search for Dr. Schnellmann’s successor began in January with a request to all ASPET members to nominate qualified candidates. Approximately 30 individuals were nominated, and the BPT Executive Committee worked through the spring and summer to complete the selection process.
Dr. Jarvis received bachelor’s degrees in psychology and philosophy, both Magna Cum Laude, in 1980 and an M.S. degree in experimental psychology in 1982, all from Old Dominion University, Norfolk, VA. Dr. Jarvis received his Ph.D. degree in behavioral neuroscience from Rutgers, The State University, New Brunswick, NJ, in 1986. His dissertation was titled "Neurochemical and functional consequences following the repeated administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)".
Dr. Jarvis is a Volwiler Research Fellow and Associate Director for Pain Modulation/Ion Channels in the Neuroscience Research Division of Abbott Laboratories, Abbott Park, IL.
He has served on JPET’s editorial board since 2002 and has been an associate editor for the Journal since 2004. He serves on the editorial boards of the British Journal of Pharmacology, Biochemical Pharmacology, Drug Development Research, Molecular Pain (charter member), and Purinergic Signalling (charter member). Dr. Jarvis has been active in Society affairs. He served on the Nominating Committee for 2006-2007, is chair of the Drug Discovery, Development, and Regulatory Affairs Division, and was recently appointed to the newly formed Web Advisory Committee.
Prospective JPET authors should note that the manuscript submission process will not change with the change in editors. All submissions will continue to be handled through the Journal’s online manuscript system (submit- jpet.aspetjournals.org).
JPET is currently in its 100th year of publication. Created by John Jacob Abel, JPET’s first issue was published in June of 1909, about six months after ASPET was founded. The Special Libraries Association recently recognized JPET as one of the 100 most influential journals in biology and medicine over the last 100 years. Other journals selected for this honor include Science, Nature, JAMA, Cell, and the New England Journal of Medicine.
RSS Feeds Available from all ASPET Journals!
Feed options include:
• Current Issue (all journals) • Recent Issues (all journals) • Fast Forward Articles (JPET, PharmRev, MolPharm, & DMD) • Subject Headings (JPET)
A Publication of the American Society for 84 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
Public Affairs/
Government Relations
Visit ASPET's new web site at www.aspet.org for updated government and public affairs related matters of interest to pharmacologists. Hit the Advocacy/Policy Updates & News link on the Home Page to sign up for RSS feeds.
And remember to follow news on TWITTER: www.twitter.com/aspet
NIH Appropriations
Congress returned to Washington September 8 to try to complete their appropriations bills and some other important legislative matters. While health care reform dominates, lawmakers want to finish spending bills as soon as they can to clear the path for health care legislation in October. But no schedule has been set for Congressional action and it does not seem possible that spending bills could be completed when the FY2010 fiscal year begins on October 1.
The FY 2010 funding status for NIH follows: The House bill provides a 3.14% increase above the FY 2009 level. The Senate bill provides a 1.47% increase above the FY 2009 level (consistent with President Obama's recommendation). The research community had recommended a 7% increase for NIH in FY 2010. Both bills must be reconciled to iron out spending and policy differences. There seems to be strong consensus within Congress that anything beyond the House figure is necessary given the $10 billion in stimulus funding NIH received 2009-2010. There also is appreciation for NIH needing additional funding in 2011 when stimulus funding ends to provide a softer landing. But there is no commitment at this time to increase funding adequately in 2011 and beyond to provide for that soft landing.
Among the policy differences of note are both House and Senate Appropriations Committees included Class B dealer language in the Committee Reports that accompanied the FY 2010 Labor-HHS-Education funding bills. Report language is not law, but government agencies can be held accountable by Congress if they do not follow Congress' intent. The House and Senate Committees cite the NAS/ILAR panel’s conclusion that random source dogs and cats are needed in NIH funded research but that it was not “necessary” to obtain these animals from Class B dealers.
The House report notes the NAS/ILAR panel's concerns regarding the adequacy of existing alternatives to Class B dealers, stating that the Committee “would like to eliminate the use of Class B dealer animals in NIH research, but also wants to be certain that sufficient supplies of non-Class B dealer random source animals exist.” The House report asks NIH to submit a report by April 1, 2010 explaining how the agency will meet these recommendations including a timeline to identify when "a sufficient pool of random source animals will exist so that NIH can prohibit the use of Class B dealer animals in its funded research.”
The Senate Committee Report language is more problematic. Instead of expressing concern about existing alternative sources, the Committee report calls for NIH to “phase out, as quickly as possible, the use of any of its funds for the purchase of or research on, dogs and cats obtained from those USDA-licensed Class B dealers who acquire dogs or cats from third parties (i.e., individuals, dealers, breeders, and pounds) and resell them.” The Senate report also states that that NIH “should not award any new grants or contracts that involve such animals and should immediately begin supporting alternative sources of random source animals from non-Class B dealers.”
ASPET-Advocacy Outreach Program
ASPET’s advocacy outreach program will make a presentation at Vanderbilt on September 30. The purpose of this outreach effort is to educate and train graduate students, post-docs and faculty in pharmacology departments on the importance of grassroots advocacy in support of increased funding for the NIH. The ultimate goal of the outreach program is to 1) develop a cadre of interested individuals who will more effectively advocate on critical issues of science funding and science policy and 2) provide individuals the skills needed to become informed and proactive participants in these issues at whatever institution the may find themselves in the near future. In the last three months, ASPET has also visited UT Southwestern, Emory University, and Wayne State for Michigan's Annual Research Colloquium. If there is an opportunity for ASPET to make a presentation in 2009 or 2010 at your institution, contact Jim Bernstein at [email protected]. A Publication of the American Society for 85 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
PUBLIC AFFAIRS/GOVERNMENT RELATIONS
Darwin 150
A volunteer campaign with media partners like National Geographic has created a Facebook campaign to gather millions online to celebrate the 150th anniversary of Darwin's "On the Origin of Species." For additional details about this and related projects visit: www.Darwin150.org
NIH Grant Funding Information Available
NIH has announced a new, user-friendly system that makes comprehensive funding information for NIH grants and contracts available on the NIH Research Portfolio Online Reporting Tool (RePORT). The new system combines NIH project databases and funding records, PubMed abstracts, full-text articles from PubMed Central, and information from the U.S. Patent and Trademark Office with a robust search engine, allowing users to locate descriptions and funding details on NIH-funded projects along with research results that cite the NIH support. http://www.nih.gov/news/health/sep2009/od-04.htm http://RePORT.nih.gov
Summer 2010 Training Opportunity: NIGMS Summer Short Courses In integrative & Organ Systems Pharmacology
The National Institute of General Medical Sciences will again fund four summer short courses that provide specialized training for using intact organ systems and in vivo animal models in the conduct of research. The purpose of each short course is to introduce graduate students, post-docs, and Ph.Ds to the knowledge and skills needed for integrative studies of organ systems and intact animals, and the physiological and biochemical responses of these systems to drugs. These critical skills are in short supply and graduate students and Ph.Ds with these skills are in great demand in both academic and industrial settings. For additional information view: http://www.aspet.org/Page.aspx?id=175&linkidentifier=id&itemid=175
ASPET-IOSS Fund Application Guidelines
The ASPET-IOSS Fund was created to provide support for graduate students and post-doctoral researchers seeking training in integrative, whole organ systems sciences. The fund is currently supported by Abbott Laboratories, Merck Research Laboratories, Pfizer, and Wyeth Research. The goal is to help augment training of students in this field. For details visit: http://www.aspet.org/Page.aspx?id=175&linkidentifier=id&itemid=175
Keep Us Informed…
Have you moved, changed jobs, or graduated? Be sure to keep ASPET informed of any changes.
You may update your information at www.aspet.org by logging in as a member or send an email to: [email protected]
A Publication of the American Society for 86 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
DIVISION NEWS
DIVISION EXECUTIVE COMMITTEES 2009 - 2010
BEHAVIORAL PHARMACOLOGY DIVISION Christine K. Carrico, Staff Liaison
Michael A. Nader, Chair DRUG METABOLISM DIVISION Charles P. France, Past Chair Emily M. Jutkiewicz, Secretary/Treasurer Jeffrey C. Stevens, Chair Leonard L. Howell, Past Secretary/Treasurer J.S. S. Leeder, Chair-Elect William E. Fantegrossi, Councilor Thomas A. Kocarek, Past Chair Lance R. McMahon, Councilor Michael H. Court, Secretary/Treasurer Ellen A. Walker, Councilor Melissa Runge-Morris, Past Secretary/Treasurer Jeffrey M. Witkin, Councilor Xiaobo Zhong, Councilor Kevin S. Murnane, Student Representative Peter W. Swaan, Councilor Susan K. Wood, Postdoctoral Representative Michael R. Wester, Councilor David R. Sibley, Council Liaison Natasha T. Snider, Student Representative Christine K. Carrico, Staff Liaison Xi He, Postdoctoral Representative James R. Halpert, Council Liaison CARDIOVASCULAR PHARMACOLOGY DIVISION Eric F. Johnson, Ex Officio Christine K. Carrico, Staff Liaison Debra Diz, Chair Nancy J. Rusch, Past Chair INTEGRATIVE SYSTEMS, TRANSLATIONAL, & John C. Kermode, Secretary/Treasurer CLINICAL PHARMACOLOGY DIVISION David B. Averill, Secretary/Treasurer-Elect Dennis C. Marshall, Chair Edwin K. Jackson, Past Secretary/Treasurer Darrell R. Abernathy, Member William M. Armstead, Member Hamid I. Akbarali, Member Alan Bass, Member Alex F. Chen, Member Dayue Duan, Member George J. Christ, Member Ryan M. Fryer, Member Ahmed F. El-Yazbi, Member Richard H. Kennedy, Member Andrea Gaedigk, Member Amy Arnold, Student/Fellow Shinya Ito, Member Biny K. Joseph, Student/Fellow Evan D. Kharasch, Member Hossam A. Shaltout, Student/Fellow Richard B. Kim, Member Suzanne G. Laychock, Council Liaison Ismail Laher, Member Christine K. Carrico, Staff Liaison Jules T. Mitchel, Member Jeffrey Paul, Member DRUG DISCOVERY, DEVELOPMENT & Honorio Silva, Member REGULATORY AFFAIRS DIVISION Richard E. White, Member James E. Barrett, Council Liaison Michael F. Jarvis, Chair Christine K. Carrico, Staff Liaison Kenneth D. Tew, Chair-Elect Gary D. Novack, Past Chair MOLECULAR PHARMACOLOGY DIVISION Tom J. Parry, Secretary/Treasurer Timothy A. Esbenshade, Secretary/Treasurer-Elect Alan V. Smrcka, Chair Richard H. Alper, Past Secretary/Treasurer J. David Port, Chair-Elect Craig Beeson, Member Kim A. Neve, Past Chair Anindya Bhattacharya, Member John R. Hepler, Secretary/Treasurer Jerry J. Buccafusco, Member Myron L. Toews, Past Secretary/Treasurer Robert W. Caldwell, Member Carmen W. Dessauer, Member Ronald L. Dundore, Member Theresa M. Flitz, Member Robert J. Leadley, Jr., Member Randy A. Hall, Member Tomas Navratil, Member Robert A. Nicholas, Member Rebecca A. Roof, Member Rennolds S. Ostrom, Member Shiladitya Sengupta, Member Dianne M. Perez, Member Janice L. Stickney, Member James E. Porter, Member Jennifer Bomberger, Student/Fellow John J. Tesmer, Member Stephanie M. Piecewicz, Postdoctoral Representative Val J. Watts, Member James E. Barrett, Council Liaison A Publication of the American Society for 87 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
DIVISION NEWS
Fiona Murray, Postdoctoral Representative Richard R. Neubig, Council Liaison Christine K. Carrico, Staff Liaison Have you Joined a
NEUROPHARMACOLOGY DIVISION Division? Margaret E. Gnegy, Chair P. Jeffrey Conn, Past Chair Linda Dykstra, Secretary/Treasurer Take full advantage of ASPET Margarita L. Dubocovich, Past Secretary/Treasurer Membership by joining a Christian C. Felder, Member Division!! Peter W. Kalivas, Member Elliott Richelson, Member Joju George, Student Representative Sara J. Ward, Postdoctoral Representative Susan G. Amara, Council Liaison You can participate in Christine K. Carrico, Staff Liaison creating the scientific
PHARMACOLOGY EDUCATION DIVISION program for the annual meeting. George A. Dunaway, Chair Jordan E. Warnick, Past Chair Amy L. Wilson-Delfosse, Secretary/Treasurer Jack W. Strandhoy, Past Secretary/Treasurer Jeffrey S. Fedan, Member John L. Szarek, Member You can network with Brian M. Cox, Council Liaison Joey V. Barnett, Ex Officio people in your field at Christine K. Carrico, Staff Liaison the mixers and
TOXICOLOGY DIVISION divisional programming at the annual meeting. Qiang Ma, Chair John D. Schuetz, Chair-Elect Mary E. Vore, Past Chair Wayne L. Backes, Secretary/Treasurer John H. Richburg, Past Secretary/Treasurer You can participate in Brian M. Cox, Council Liaison Christine K. Carrico, Staff Liaison running the division and planning its activities.
You get special notices and newsletters about items and activities of interest in your field.
A Publication of the American Society for 88 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
CHAPTER NEWS
Mid-Atlantic Pharmacology Society 2009 Annual Meeting: Temple University Health Sciences Center College of Medicine Philadelphia, PA, November 2, 2009
Nuclear Receptors: From Evolution of Concept to State-of-the-Art Methods and Knowledge
7:45 AM Registration and Continental Breakfast Poster Set up
8:30 AM Temple University Welcome Deans Peter Doukas, PhD and John Daly, PhD
8:45 AM MAPS Welcome Vincent J. Aloyo, President, MAPS
8:50 AM Introduction to Program Nae Dun, PhD, Temple University School of Medicine
9:00 AM Alternative Approach: From the Swiss Alps to Nuclear Reactors Elwood Jensen, PhD, University of Cincinnati Medical Center
9:55 AM Nuclear Receptor Coactivators: Physiology and Pathology Bert W. O’Malley, MD, Baylor College of Medicine
10:50 AM Refreshment Break
11:10 AM Nuclear Receptors and Metabolism Mitchell A. Lazar, MD, PhD, University of Pennsylvania
11:55 AM Koelle Award Presented by Robert N. Willette, PhD
12:15 PM Lunch and Poster Viewing/Judging
2:15 PM Retinoic Acid Receptors: Mediators of Retinoid Action Dianne R. Soprano, PhD, Temple University
3:00 PM Liver X Receptor: A Novel Therapeutic Target for Dermal Inflammatory Indications Sunil Nagpal, PhD, Wyeth Research
3:45 PM Poster Awards Presentations Sri Ghatta, PhD
4:15 – 5:00 PM Reception
For more information visit: http://www.aspet.org/MAPS_Meeting/
For meeting brochure and details, contact: Ms. Carol Imbesi (215-762-2353) or [email protected] Fax 215-762-2299
A Publication of the American Society for 89 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
MEMBERS IN THE NEWS
Frederick P. Guengerich, PhD received the third annual American Association for Cancer Research Award for Outstanding Achievement in Chemistry in Cancer Research. The award is given for outstanding, novel, and significant chemistry research that has led to important contributions to the fields of basic cancer research, translational cancer research, cancer diagnosis, the prevention of cancer, or the treatment of patients with cancer. Dr. Guengerich was honored for his studies on the role of human cytochrome P450 in the metabolic activation of carcinogens to intermediates that mutate genes. He has also made major advances in the understanding of the reactions of metabolically activated carcinogens with DNA to form adducts, defining the details of mechanisms of several classes of carcinogens including the arylamines, vinyl halides, and dihaloalkanes.
This announcement was taken from ASBMB Today.
Andrea Cignarella, PhD has been selected as a visiting Fulbright Scholar for the academic year 2009-10. During her scholarship (February – July 2010), she will be working at the Fred Hutchinson Cancer Research Center in Seattle in the lab of Dr. Mario Kratz.
Evan D. Kharasch, MD, PhD has been named interim vice chancellor for research at Washington University in St. Louis. The appointment was effective July 20. As interim vice chancellor, Kharasch will be the chief officer responsible for the University's research mission, overseeing an enterprise that generates more than $500 million for sponsored research from a wide array of funding sources. He will become the institutional official responsible for all compliance programs that oversee the University community's adherence to guidelines governing laboratory animal care and use and research involving human volunteers. His areas of oversight also will include the development of research policies, management of grants and contracts, the continuing education of faculty and staff regarding research regulations, issues related to conflict of interest and research integrity, and intellectual property and technology transfer. For the full story, please visit: http://mednews.wustl.edu/news/page/normal/14383.html?emailID=25003
STAFF NEWS
David Williams, JPET’s Senior Editorial Coordinator, will be resigning from the ASPET office as of September 28, 2009. After nine years of dedicated service to ASPET, David will be moving back to his hometown of Kansas City. David recently completed his Master of Public Health degree and is currently interviewing for positions in his field. David’s easy-going and friendly personality will be missed by staff; however, we all wish him the best of luck in all his future endeavors! ASPET will be having a farewell party for David on September 25.
Cassandra Wood, has been promoted to Editorial Coordinator for JPET. As of September 29, she will be the primary contact for the journal. Her responsibilities will expand to include the processing of accepted manuscripts for publication, and working more closely with the Associate Editors of JPET and the printers at Cadmus. She will also assist authors with the process of submitting their articles in the online system. We congratulate Cassie on her promotion and hard work!
Share With Us and the ASPET Membership…
Your Announcements, Promotions, Achievements, and News
Please send us your news, along with a picture to:
Suzie Thompson, [email protected]
A Publication of the American Society for 90 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
NEW ASPET MEMBERS ASPET WELCOMES THE FOLLOWING NEW MEMBERS:
REGULAR MEMBERS:
Diane Allen-Gipson, Univ of Nebraska Medical Ctr Alexei G. Basnakian, MD,PhD, Univ of Arkansas for Medical Sciences K. Ulrich (Ulli) Bayer, PhD, Univ of Colorado Denver William E. Burmeister Jie Cheng, PhD, National Cancer Institute Dermot M. Cooper, BSPhD, Univ of cambridge Theodore R. Cummins, PhD, Indiana Univ School of Medicine Stark Neurosciences Rsch Inst M. Imad I. Damaj, PhD, Virginia Commonwealth Univ Carmen W. Dessauer, PhD, Univ of Texas Health Science Center Denis J. Dupre, PhD, Dalhousie Univ William A. Eckert, III, PhD, Johnson & Johnson Pharmaceutical R & D, LLC Karin F. Ejendal, PhD, Purdue Univ Kei-lai L. Fong, PhD, Aptuit Consulting Inc. Tzu-fun Fu, PhD, National Cheng Kung Univ Lei Gao, PhD, Univ of Pennsylvania Amadeu Gavalda, PhD, Almirall Ismael J. Hidalgo, PhD, Absorption Systems, LP Peter S. Hodder, PhD, The Scripps Research Institute Andrea G. Hohmann, PhD, Univ of Georgia Heather A. Hostetler, PhD, Wright State Univ Nina Isoherranen, PhD, Univ of Washington Allan Kalueff, Tulane Medical School Edward J. Kelly, PhD, Univ of Washington Randall J. Kimple, MD, PhD, Univ of North Carolina-Chapel Hill Uday Kompella, Univ of Colorado - Denver Tatiana G. Kutateladze, PhD, Univ of Colorado - Denver Chuan Li, PhD, Shanghai Institute of Materia Medica, CAS Dora Babu Madhura, PhD, Univ of Minnesota Donna L. Maier, PhD, AstraZeneca Jonathan Maybaum, PhD, Univ of Michigan Stanley T. Motley, MS, Johnson & Johnson PRD James S. Polakowski, BS, Abbott Laboratories Satyanarayana R. Pondugula, PhD, St. Jude Children's Research Hospital Roseanna L. Popp, PhD, Texas Tech Univ Health Sciences Center Bruce A. Posner, PhD, Pfizer, Inc Sanda Predescu, PhD, Rush Univ Medical Center Maria Sergeeva, PhD, Anadys Pharmaceuticals, Inc Ting Shi, PhD, Cleveland Clinic Foundation Honorio Silva, MD, Project Globe Consortium for CPD Robert H. Spencer, PhD, Cara Therapeutics Junko Sugatani, PhD, Univ of Shizuoka Graduate School of Pharmaceutical Sciences Elisabet Vila Calsina, MD, PhD, Universitat Autònoma de Barcelona Richard E. White, Medical College of Georgia Virginia E. Wotring, DPhil, NASA Johnson Space Center Christine C. Wu, PhD, Univ of Colorado School of Medicine Takahiro Yamauchi, MD, PhD, Univ of Fukui Faculty of Medical Sciences Jing Yang, PhD, Univ of California - San Diego Anne Zajicek, MD, NICHD Huina Zhang, MD, PhD, Univ of Michigan Lin Zhang, PhD, Univ of Pittsburgh Xianming Zhang, PhD, Univ of Illinois-Chicago
A Publication of the American Society for 91 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
NEW ASPET MEMBERS
GRADUATE STUDENT MEMBERS:
Syed M. Ahmed, BS, Univ of Toronto Abayomi M. AjAyi, MSc, Kampala International Univ Lloyd F. Alfonso, MPharm, Texas Tech Univ Health Sciences Center Khalid M. AlHarthy, BS, King Saud Univ Namrata Bhatnagar, PhD, North Dakota State Univ Kavaljit H. Chhabra, MPharm, Louisiana State Univ Health Sciences Center Hosam A. Elbaz, BPharm, West Virginia Univ Omotayo O. ErEjuwa, BSc, Univ Sains Malaysia School of Medical Sciences Amanda W. Hui Chyn, BSc, Univ Putra Malaysia Institute of Bioscience Jong Moo Kim, BSc, The Univ of British Columbia Yogesh A. Kulkarni, MPharm, SVKM's NMIMS Univ Shimon Lecht, MSc, The Hebrew Univ of Jerusalem Sharika S. Lewis, Texas Southern Univ Helena S. Mistry, PhD, Univ of Toronto Carlos A. Monroy, BA, Univ of Iowa Melanie Mueller, Johns Hopkins School of Medicine Atish K. Prakash, MPharm, Panjab Univ Kelly E. Radford, PharmD, Vanderbilt Univ Keelia Rhoads, Univ of Wisconsin-Madison Kathleen E. Rogers, BS, Johns Hopkins Univ E. Aaron Runkle, BS, Penn State College of Medicine Tiffani Slaughter, Jackson State Univ Rachel Tanos, PhD, Pennsylvania State Univ Christopher M. Thomas, PharmD, Vanderbilt Univ Suneeta Tumati, PhD, Univ of Arizona Lauren E. Van Atta, BA, Lipscomb Univ College of Pharmacy Scott J. Webster, BS, Medical College of Georgia Endrit Ziu, Univ of Arkansas for Medical Sciences
UNDERGRADUATE STUDENT MEMBERS:
Karen E. Adcock Alexandra Amaro-Ortiz, Univ of Puerto Rico Khadija Amin, Univ of California - San Diego Sara J. Arnold, Univ of Texas - Dallas Suraj Aryal, Univ of Colorado - Denver Alexander B. Balmaceda, Univ of Kansas William Bechtold, Allegheny College Lisa Becks, Louisiana State Univ Health Sciences Center Samantha L. Bell, Univ of Pittsburgh Alexander G. Bick, Vanderbilt Univ Chelsea J. Buma, Westminster College Brian P. Chalmers, Kansas Univ Medical Center Alisha Chitrakar, Saint Peter's College Jacqueline E. Crain, Shawnee Mission East High School Caroline E. Crocker, Univ of Texas Health Science Center Joshua D. Cronk, Univ of Michigan Medical School Jenniffer Darnell, Washington State Univ Christopher R. Deig, Wabash College Adam Dziuba, Univ of Michigan Kevin C. Flanagan, Univ of Kansas Medical Center Chase R. Foy, Case Western Reserve Univ Leanna R. Gentry, Univ of North Carolina at Chapel Hill Michael R. Gionfriddo, Wilkes Univ
A Publication of the American Society for 92 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
NEW ASPET MEMBERS
Jean Y. Guan Lauren J. Heath, Univ of Michigan Joy M. Holowicki, Benedictine Univ Jacob C. Hostetler, Univ of Arkansas Medical Sciences Stephen R. Karpen, The Univ of Arizona Lawrence L. Lau, Univ of California-San Diego Christian Legaspi, Washington State Univ Bryan A. Leland, Grinnell College Cayleih Mackay, Washington State Univ Jenna Mackay, Washington State Univ Matthew A. Mandelbaum, Univ of Arkansas Medical Sciences Sarah A. Martin, North Central College Brett A. McGregor, Univ of North Dakota Arwa K. Mesiwala, Arwa Mesiwala Jacqueline Moran, Univ of California - San Diego Nicola K. Muchatuta, Kennesaw State Univ Surafel G. Mulugeta, Vanderbilt Univ Suzanne Y. Ngo, Univ of Colorado - Denver Phi V. Nguyen, Univ of Colorado - Denver Sida Niu, Univ of Kansas Medical Center Nicholas M. Novak, Oberlin College Maria C. Palazzo, Vanderbilt Univ Nikita J. Patel, Univ of Colorado - Denver Iryna V. Polyakova, Univ of Arkansas Medical Sciences Kristin M. Prause, Univ of Colorado - Denver Alicia Proctor, Washington State Univ Maryam Rahman, McMaster Univ John M. Saathoff, Eastern Illinois Univ Amanda R. Saffell, Univ of Arkansas for Medical Sciences Benjamin S. Schwartz, Univ of Michigan Samantha M. Shaw, Michigan State Univ Erin V. Shea, Univ of Michigan Andrea M. Slusser, Minnesota State Univ Ashley M. Stevens, Case Western Reserve Univ Veronica G. Taylor, Gustavus Adolphus College Sarah A. Thomas, Michigan State Univ Daniel C. Totten, Univ of Arkansas Medical Sciences Ngoc Mai Lam Vuong, Washington State Univ Brett R. Westbrook, Univ of Arkansas for Medical Sciences Corissa White, Washington State Univ Jennifer G. Whitesides, King College Katie Wyrick, Washington State Univ
RECRUIT AN ASPET MEMBER!
Do you have a friend, colleague or student who is not yet an ASPET member? Be sure to tell them about ASPET membership!
Members receive benefits including: Free Access to all 5 ASPET journals, Reduced rates to publish in ASPET journals, Reduced rates to attend Experimental Biology, plus much more!
Why not share these great benefits? For more information about membership in ASPET and all the benefits we offer, be sure to visit: www.aspet.org
A Publication of the American Society for 93 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
IN SYMPATHY
ASPET notes with sympathy the passing of the following members:
Anthony J. Hance, PhD
Arthur S. Keats, MD
Sachindra N. Pradhan, MD, PhD
A Publication of the American Society for 94 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
OBITUARY
Robert F. Furchgott (1916-2009) was born in Charleston, South Carolina on June 4, 1916. He received his primary education locally, earned a BS in chemistry in 1937 from the University of North Carolina, and obtained a PhD in biochemistry from Northwestern University in 1940. The topic of his dissertation was on the physical chemistry of mammalian red blood cells in relation to their structure. The investigation resulted in five publications on the topic. Between 1940 and 1949, Furchgott served as a research fellow, instructor in physiology, and Assistant Professor of Biochemistry in Medicine at the Cornell University Medical School. In 1949, Oliver Lowry of Washington University invited Furchgott to join the Department of Pharmacology where he stayed Image credits to the for seven years. Besides teaching assignments, Furchgott investigated the effects of sodium Nobel Foundation fluoroacetate, succinate, anoxia, pH and vasoactive substances on the activity of the smooth muscle. Although vascular tissue was used before by Charles Sherrington, in 1953, Furchgott and S. Bhadrakom introduced a versatile method in vitro for the study of the blood vessel. The method remained popular through the ages. While working in the laboratory, Furchgott observed that the organ bath containing the blood vessel exposed to the incoming sunlight by the window produced a gradual vascular relaxation as compared to the other organ bath in the shade. The discovery of photorelaxation of the vascular smooth muscle and the effect on drugs on this process was reported by Furchgott in 1955. The same year, Furchgott published a comprehensive report on the pharmacology of vascular smooth muscle in pharmacological reviews.
In 1956, Professor Furchgott chaired the Department of Pharmacology at the Downstate Medical Center, Brooklyn of the State University of New York. He studied adrenergic mechanisms and developed the theory of drug-receptor interactions. Relative receptor selectivity of the irreversible blocker dibenamine against different agonists was reported. He was one of the first pharmacologists to examine the functional importance of neuronal uptake of norepinephrine and epinephrine in the organ system. After R.P. Stephenson and Mark Nikenson in 1956 independently concluded the existence of the receptor reserve, Furchgott in 1967 pioneered the theoretical basis of receptor reserve. The meaning of affinity as represented by EC50 and the maximal effects of the potent agonist derived from the dose response curve on the isolated organ with the receptor reserve was questioned. Furchgott and Paula Bursztyn reported a method to calculate the dissociation constant and relative intrinsic efficacy of agonists on the isolated organs. The method involves the use of irreversible blocker to inactivate the reserve fraction of receptors so that the maximal effect of the agonist is achieved by saturation of the remaining available receptors. Different organs in the body contain a different percent of the receptor reserve. In aging as well as in pathological state, the reserve can decrease. This creates a problem in selecting the correct dose of the drug in the treatment.
John Gaddum, Heinze O. Schild, and R.F. Furchgott are considered important pillars in developing the useful methodology for investigating competitive antagonists. Furchgott observed that the linear Schild plot of agonist: antagonist interaction with the slope of 1 can be distorted if there is a site of loss for the agonist at the neuroeffector junction. Studies on competitive antagonists are of great importance in classification and subclassification of receptors. In the early 1970s, Furchgott had exceptional investigators like S.M. Kirpekar, P.S. Garcia, Peter Cervoni, O.S. Steinsland, Arun Wakade, and J.C. Prat who contributed to the functional understanding of the autonomic neuroeffector junction. The role of neuronal receptor mechanisms in the control of the transmitter was elucidated. A. Jurkiewicz, N.H. Jurkiewicz, J.C. Besse, R.A. Sorace, J.S. Stollak, M.T. Khan, D. Davidson, S. Walker, Taruna Wakade, S-F. Wu and C.I. Lin joined the group later. On the personal level, he was an excellent mentor who sparked the careers of many scientists.
R.F. Furchgott and J.V. Zawadzki, in 1980, reported the obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine in Nature. During the next eight years, Furchgott and his team discovered that muscarinic cholinergic activation of the vascular endothelial cells releases nitric oxide, a very potent vasodilator. A new group of investigators like P.D. Cherry, D. Jothianandan, M.H. Carvalho, W. Martin, G.M. Villani, K. Matsunaga, A.S. Khan, and A.S. Gidari joined Furchgott's laboratory for elucidating the story of nitric oxide. In 1989, Robert Furchgott was invited to Stockholm to deliver the Ulf von Euler Lecture.
During his lifetime, Furchgott served as visiting professor and a guest speaker at universities around the world. In 1988 he was appointed Distinguished Professor at the Downstate Medical Center Pharmacology Department where he served as the Chairman. Professor Furchgott received numerous awards and Honorary Doctorate degrees from universities in Spain, Belgium, the University of North Carolina and The Ohio State University. In 1990, he was elected a member of the National Academy of Sciences. Robert F. Furchgott shared the 1998 Nobel Prize in Physiology or Medicine with Louis Ignarro and Ferid Murad. On May 19th, the world lost a great American scientist who was the major architect of pharmacology.
Prepared by Popat N. Patil, Emeritus Professor of Pharmacology, College of Pharmacy, The Ohio State University. A Publication of the American Society for 95 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
OBITUARY
Sachindra N. Pradhan, MD, PhD
The journey of Sachindra Nath Pradhan, MD, PhD began at a remote village in India where he grew up under meager conditions. In his village, there was no electricity, running water, and he walked miles in barefoot to attend school. As a child, he lost his mother very early. But driven by his quest for education and science, he endured grave hardship and overcame obstacles to see himself through his academic career. One of the early Indian immigrants in the United States, he persevered on his own to build his scientific career but never forgot his roots. He funded scholarships, provided shelter and support to many Indian graduate students during his tenure. Influenced by the principles of Mahatma Gandhi, he lived a very simple life, established a charitable Trust, ‘Pradhan Foundation’ for poor and needy students for education and scientific advancements.
Dr. Sachindra Nath Pradhan, a former ‘Distinguished Professor of Pharmacology’ at Howard University School of Medicine, died at his home in Bethesda on March 21. He died at age 89, from complications of a stroke. He is survived by his beloved wife, Dr. Sikta Pradhan.
A native of West Bengal, India, Dr. Pradhan received his MD degree in 1945 from Calcutta Medical College, Calcutta University and did his graduate studies at the School of Tropical Medicine, Calcutta. In 1953, Dr. Pradhan came to the United States as a Visiting Scientist to the National Cancer Institute of the National Institutes of Health. He also pursued graduate studies in pharmacology and received his PhD degree in 1959 from George Washington University, Washington, DC.
Dr. Pradhan joined Howard University in 1955. He had a long and accomplished research career in the Department of Pharmacology at Howard University College of Medicine (HUCM) , Washington, DC. In addition to teaching, Dr. Pradhan conducted research on neuropsychopharmacology. He was the recipient of millions of dollars of research funds from both government and non-governmental organizations. Scores of graduate students were trained in his laboratory. He published over 130 scientific papers and contributed 50 reviews, monographs and chapters in several scientific books. He published four books including, “Drug Abuse: Basic and Clinical Aspects” (Mosby) and the text book, “Pharmacology in Medicine: Principles and Practice” (SP Press International). He was a fellow of the American College of Neuropsychopharmacology, American Society for Pharmacology and Experimental Therapeutics, American Association of Cancer Research, and the New York Academy of Science. He also served as a scientific consultant to the US Food and Drug Administration. He served as member of the Editorial Boards of journals, Arch Internat. Pharmacodyn., Advances in Alcohol & Substance Abuse, Progress in Neuropsychopharmacology, Psychopharmacology, etc.
On leave from Howard University College of Medicine, he served as the Head, Division of Pharmacology, Central Drug Research Institute, Lucknow, India from 1962 to 1964. Dr. Pradhan’s legacy included significant endowments to advance education in India (his hometown of District of Midnapore, West Bengal). As a result of his other noteworthy philanthropic efforts, the research facilities, “SN Pradhan Center of Neurosciences” was established at Calcutta University.
Dr. Pradhan was an accomplished scientist, a patriotic Indian, and a visionary. Last but not least, Dr. Pradhan will be remembered by his friends for his humanity, benevolence, and love of nature and his appreciation of the Arts.
Submitted by Sikta Pradhan, PhD, wife of Sachindra N. Pradhan, MD, PhD
A Publication of the American Society for 96 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
ASPET Products Now AvailableOnline at: http://www.aspet.org/store/
ASPET Stuffed Donkey: Cute and cuddly 9” stuffed donkey wearing an ASPET t-shirt. Members pay just $15.00 plus ship- ping. ASPET T-Shirt: Choose from 2 styles, all sizes available. Just $15.00 plus shipping for members. ASPET Hat: Beige hat with ASPET logo. Fits all sizes. Members pay $12.00 plus shipping. ASPET Compendium: Special publication containing articles written for the Centennial celebration. Members pay $25.00 plus shipping. ASPET Ornament: Holiday ornaments with the ASPET logo. Makes a great gift for col- leagues! Members pay $5.00 plus shippng. ASPET Wineglass: A commemorative wineglass cele- brating ASPET’s 100th Anniversary. Members pay $5.00 plus shipping. ASPET Water Bottle: Refresh yourself with an ASPET water bottle. Members pay $10.00 plus shipping. Order your ASPET Products Today! Above rates apply for ASPET members only. For large orders or any questions, contact Suzie Thompson, [email protected] / 301-634-7916 MEMBERSHIP INFORMATION
Definitions of Categories of ASPET Membership
Regular Members: Any doctoral level investigator who has conducted and is the primary author on at least one publication of an original study in the area of pharmacology published in a peer-reviewed journal is eligible for membership in ASPET. Exceptions may be made for someone who does not meet the degree requirement but who has made major research contributions to pharmacology. Dues for regular members are $140/year. Regular members must be nominated by one (1) Regular or Retired ASPET member.
Affiliate Members: An investigator who does not meet the requirements for Regular membership because of the lack of a degree or lack of publication is eligible to apply for Affiliate membership. Affiliate members receive all the same member benefits as Regular members except that they may not vote in ASPET elections. Dues for Affiliate members are $105/year. Affiliate members must be nominated by one (1) Regular or Retired ASPET member.
Student Members: Individuals who are enrolled in undergraduate, graduate, or professional degree programs are eligible for Student membership in ASPET. Student members receive all the same benefits as Regular Members except that they may not vote in ASPET elections. Individuals may remain in the Student Member category for up to two (2) years following completion of their research doctoral degree. Undergraduate students pay no dues. Dues for second year and above Student members are $30. Student members must be nominated by one (1) Regular or Affiliate ASPET member.
Sponsors should send an email or letter addressing the applicant’s qualifications for ASPET membership directly to the ASPET office ([email protected]).
Regular Member Benefits (Dues $140): Affiliate Members (Dues $105) have all the benefits of • Reduced page charges for corresponding authors to Regular Members except they may: publish in ASPET journals – pay $40/page instead of • Sponsor candidates for Student membership only. $80/page and save enough with one four-page article • Not sponsor a paper for a non-member at a Society to pay your annual ASPET dues! meeting. • Half-price color fees to publish color figures in ASPET • Not vote in Society elections. journals. • Not hold an elected office in the Society. • Free full-text access to all five online ASPET journals, including all back issues. Student Members (Dues $30) have all the benefits of • Free subscription to Molecular Interventions (print) and Regular Members except they: The Pharmacologist (online). • Pay no dues their first year. • Reduced subscription rates for ASPET print journals. • Pay only $30 annual dues thereafter. Undergraduate • Reduced registration fees for ASPET meetings. student members pay no dues and get their first • Sponsorship of papers at the ASPET meeting. graduate year free. • Best abstract awards for young scientists at the • Must have their papers at Society meetings sponsored ASPET meeting. by a member. • Free listing in the FASEB Directory. • May not vote in Society elections nor hold an elected • Membership in multiple ASPET Divisions for no office in the Society. additional dues.
2010 Publication Subscription Rates for Members All Society Members qualify for the following reduced print publication subscription rates: • Journal of Pharmacology and Experimental Therapeutics (Monthly) - $220/year • Pharmacological Reviews (Quarterly) - $89/year • Drug Metabolism and Disposition (Monthly) - $137/year • Molecular Pharmacology (Monthly) - $180/year • Molecular Interventions (Bimonthly) – included with dues
APPLICATION INSTRUCTIONS Submit the completed Application for Membership form or use the online application form on the ASPET web site at http://www.aspet.org/membership/apply/. Submit a current curriculum vitae including bibliography for Regular and Affiliate Membership. You may e-mail the CV to the ASPET Membership Coordinator, Robert Phipps, [email protected].
Sponsor Statements: Submit a statement(s) of qualifications of the applicant from two Regular/Retired Members of ASPET for Regular Membership or from one Regular/Retired Member of ASPET for Affiliate Membership and Student Membership (Affiliate Members may also sponsor student applicants). In addition to the statement certifying that the applicant is qualified for ASPET membership, sponsors should provide their own current address, phone, fax, and email. It is the responsibility of the applicant to insure that these documents are submitted to the ASPET office.
A Publication of the American Society for 99 Pharmacology and Experimental Therapeutics - ASPET Volume 51 Number 3, 2009
American Society for Pharmacology and Experimental Therapeutics 9650 Rockville Pike, Bethesda, MD 20814-3995 USA Phone: 301-634-7060 ♦ Fax: 301-634-7061 ♦ www.aspet.org
Membership Application – TP0909 Please Complete All Sections:
Section 1: Application Details Section 2: Source Application for: How did you hear about ASPET:
❏ Regular Membership ❏ Meeting ______❏ Affiliate Membership ❏ ASPET Journal ______
❏ Graduate Student – Expected Date of Graduation: ______❏ Mentor ______❏ Undergraduate Student - Year: ❏ Fr ❏Soph ❏Jr ❏Sr ❏ Other ______
Section 3: Personal Information Section 4: Optional Demographics (Not Required) Name: Date of Birth: ______Sex: ❏ Female ❏ Male Institution: Ethnicity: ❏ Asian
Address: ❏ Black or African American
❏ American Indian or Alaskan Native
❏ Hispanic or Latino Telephone: ❏ Native Hawaiian or Pacific Islander
Fax: ❏ White
Other: ______Email: ❏ The information in this section will be used by ASPET to collate statistics
and will be kept private. Completion of this section is voluntary.
Section 5: Sponsor (Must be an ASPET Member)
Name and email of your sponsor:
Please have your sponsor send us a brief letter or e-mail outlining your qualifications for membership in ASPET to the Membership Coordinator , Robert Phipps, ([email protected]).
Section 6: Division Selection Divisions: Division membership is a benefit of ASPET membership and there is no additional charge to belong to a division. It is highly recommended that you join a division so that you may take full advantage of Society participation. Joining a division allows you to participate in creating the scientific program for the annual meeting, network with people in your field at mixers and divisional programs, and receive special notices and newsletters about items and activities of interest in your field. Be sure to pick a division! Indicate primary (1) and as many secondary (X) divisions to which you wish to belong: ___Division for Behavioral Pharmacology ___Division for Integrative Systems, Translational, & ___Division for Cardiovascular Pharmacology Clinical Pharmacology ___Division for Drug Discovery, Development & ___Division for Molecular Pharmacology Regulatory Affairs ___ Division for Neuropharmacology ___Division for Drug Metabolism ___ Division for Pharmacology Education ___Division for Toxicology
Section 7: Curriculum Vitae Regular, Affiliate, and Graduate Student applicants: Please send your Curriculum Vitae (including bibliography) by email to the Membership Coordinator, Robert Phipps ([email protected]).
Undergraduate Student Applicants Only:
Current Education : Expected Degree & Date: School: City/State/Country: Major Field:
Applications are reviewed on a rolling basis. Please DO NOT send payment with your application. Upon membership approval, you will be sent a dues statement and welcome package. Student Membership is FREE for the first year, Regular members pay $140, Affiliate Members pay $105. Call or e-mail the ASPET Membership Department for additional information: 301-634-7135 / [email protected].